Peng K - Search Results

1

Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics.

Peng K, Siradze K, Fischer SK. Peng K, et al. Bioanalysis. 2021 Feb;13(4):239-252. doi: 10.4155/bio-2020-0281. Epub 2021 Feb 12. Bioanalysis. 2021. PMID: 33576267

2

Clinical immunogenicity specificity assessments: a platform evaluation.

Peng K, Siradze K, Quarmby V, Fischer SK. Peng K, et al. J Pharm Biomed Anal. 2011 Feb 20;54(3):629-35. doi: 10.1016/j.jpba.2010.09.035. Epub 2010 Oct 29. J Pharm Biomed Anal. 2011. PMID: 21035975

3

Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.

Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Araujo J, et al. Among authors: peng k. J Pharm Biomed Anal. 2011 Jul 15;55(5):1041-9. doi: 10.1016/j.jpba.2011.03.008. Epub 2011 Mar 11. J Pharm Biomed Anal. 2011. PMID: 21466939

4

Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Among authors: peng k. Curr Med Res Opin. 2014 May;30(5):913-22. doi: 10.1185/03007995.2013.877435. Epub 2014 Jan 24. Curr Med Res Opin. 2014. PMID: 24354863 Clinical Trial.

5

When assay format matters: a case study on the evaluation of three assay formats to support a clinical pharmacokinetic study.

Peng K, Baker D, Brignoli S, Cabuhat J, Fischer SK. Peng K, et al. AAPS J. 2014 Jul;16(4):625-33. doi: 10.1208/s12248-014-9594-7. Epub 2014 Apr 22. AAPS J. 2014. PMID: 24752719 Free PMC article.

6

Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.

Gelzleichter TR, Halpern W, Erwin R, Baruch A, Leabman M, Forrest AS, Satterwhite CM, Peng K, Chilton J, Stevens D. Gelzleichter TR, et al. Among authors: peng k. Toxicol Sci. 2014 Aug 1;140(2):470-80. doi: 10.1093/toxsci/kfu093. Epub 2014 May 20. Toxicol Sci. 2014. PMID: 24848798

7

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Among authors: peng k. Curr Med Res Opin. 2014 Oct;30(10):1927-9. doi: 10.1185/03007995.2014.938150. Epub 2014 Jul 7. Curr Med Res Opin. 2014. PMID: 24960148 No abstract available.

8

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.

Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK. Peng K, et al. MAbs. 2014;6(6):1500-8. doi: 10.4161/mabs.36208. MAbs. 2014. PMID: 25484037 Free PMC article. Clinical Trial.

9

Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, Xue L. Gorovits B, et al. Among authors: peng k. AAPS J. 2016 Mar;18(2):311-20. doi: 10.1208/s12248-016-9878-1. Epub 2016 Jan 28. AAPS J. 2016. PMID: 26821802 Free PMC article. Review.

10

Bioanalytical challenges and improved detection of circulating levels of IL-13.

Cai F, Hornauer H, Peng K, Schofield CA, Scheerens H, Morimoto AM. Cai F, et al. Among authors: peng k. Bioanalysis. 2016 Feb;8(4):323-32. doi: 10.4155/bio.15.254. Epub 2016 Feb 5. Bioanalysis. 2016. PMID: 26847873

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,648 results

Search Page

Filters